Loading clinical trials...
Loading clinical trials...
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Conditions
Interventions
TAK-994
Placebo
Locations
70
United States
Wright Clinical Research
Alabaster, Alabama, United States
Mayo Clinic Arizona 300151190
Phoenix, Arizona, United States
CITrials - Bellflower
Bellflower, California, United States
Santa Monica Clinical Trials
Los Angeles, California, United States
Stanford School of Medicine
Redwood City, California, United States
Pacific Research Network, Inc 150118105
San Diego, California, United States
Start Date
April 30, 2021
Primary Completion Date
November 3, 2021
Completion Date
November 3, 2021
Last Updated
December 26, 2023
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions